by Portfolio Grader | January 18, 2013 1:00 pm
This week, five Pharmaceutical stocks are improving their overall ratings on Portfolio Grader. Each of these stocks is rated an “A” (“strong buy”) or “B” overall (“buy”).
This week, Pacira Pharmaceuticals (NASDAQ:PCRX) is showing good progress as the company’s rating jumps from a B (“buy”) last week to an A (“strong buy”). Pacira Pharmaceuticals is a specialty pharmaceutical company with focuses on the development, commercialization, and manufacturing of proprietary pharmaceutical products. In Portfolio Grader’s specific subcategories of Earnings Momentum and Sales Growth, PCRX also gets A’s. The stock price has risen 16.8% over the past month, better than the 2.7% increase the Nasdaq has seen over the same period of time. For more information, get Portfolio Grader’s complete analysis of PCRX stock.
Medicines Co. (NASDAQ:MDCO) ups its rating to a B (“buy”) this week after earning a C (“hold”) in the week before. Medicines develops products that improve specialized care. Wall Street seems to agree with the upgrade and has propelled the stock up 34.6% over the past month. For more information, get Portfolio Grader’s complete analysis of MDCO stock.
Forest Laboratories (NYSE:FRX) boosts its rating from a C to a B this week. Forest Laboratories develops, manufactures, and sells both branded and generic forms of ethical products which require a physician’s prescription. For more information, get Portfolio Grader’s complete analysis of FRX stock.
Eli Lilly (NYSE:LLY) shows solid improvement this week. The company’s rating rises from a B to an A. Eli Lilly discovers, develops, manufactures, and sells pharmaceutical products for humans and animals. Investors seem to agree with the upgraded status of the stock, and have pushed the stock up 8.2% over the past month. For more information, get Portfolio Grader’s complete analysis of LLY stock.
This week, Merck (NYSE:MRK) pushes up from a C to a B rating. Merck is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures. For more information, get Portfolio Grader’s complete analysis of MRK stock.
Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.
Source URL: http://investorplace.com/2013/01/5-pharmaceutical-stocks-to-buy-now-pcrx-mdco-frx/
Short URL: http://invstplc.com/1nvCZAF
Copyright ©2017 InvestorPlace Media, LLC. All rights reserved. 700 Indian Springs Drive, Lancaster, PA 17601.